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Background
A promising treatment for allergic asthma (AA) in
children is the sublingual specific immunotherapy (SLIT)
which targets mild or moderate persistent AA types.
There have not been any studies to investigate the efficacy
and safety of adding SLIT to combination therapy
(budesonide / formoterol) in asthmatic children sensitive
to house dust mite (HDM).
Aims and objectives
The aims of this current study were to evaluate the
effectiveness and safety of adding SLIT to combination
therapy (budesonide / formoterol) in HDM sensitive
children with AA over a three-year period. Another aim
of this study was to evaluate the possibility of reducing
the dose of the combination therapy on using SLIT.
Methods
This study has followed a retrospective clinical and labora-
tory data analysis. The data were classified according to
the treatment protocol given into two groups, both of
which continued their treatment plan for a period of three
years. Fifty children (Control group) who were treated
with combination therapy (budesonide 80 mg /formoterol
4 mcg), two puffs twice daily. The Control group com-
pared to fifty children (SLIT group) who were treated with
the same combination therapy plus standardised extract
50/50 Dp / Df, a dust mite SLIT. The data analyses were
conducted at baseline and after three years in each and in
between groups.
Results
The results of this study showed that SLIT group has
a highly statistically significant reduction in the use of
daily doses of the combination treatment (budesonide /
formoterol) (p<0.0001), in comparison to control group
(p=0.397). In addition, in the SLIT group there were
97% of the patients totally stopped both control and
reliever medications in the final six months and only
continued with SLIT. Moreover, there were more
improvements in FVC and FEV1 in SLIT compared to
control group. Additionally, these results revealed that
SLIT significantly reduced the clinical outcome scores.
There were no systematic (anaphylaxis) side effects
reported with SLIT.
Conclusions
The results of this study suggest that SLIT has a significant
role in controlling AA due to dust mite in children.
Besides, the results suggest that SLIT is a safe medication
for children with AA. Caution must be applied when
using the results of this study in practice due to the
retrospective design of this study, which means that the
findings may not be transferable to routine clinical
practice.
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